Increased Circulating Myostatin in Patients with Type 2 Diabetes Mellitus

Overview

Journal J Huazhong Univ Sci Technolog Med Sci

Specialty General Medicine

Date 2012 Aug 14

PMID 22886966

Citations 16

Authors

Fang Wang

Yonggan Liao

Xuefeng Li

Chunlin Ren

Changming Cheng

Yongsheng Ren

Affiliations

Soon will be listed here.

Abstract

The changes of plasma myostatin levels in patients with type 2 diabetes mellitus (T2D) and their clinical correlation were investigated. We recruited 43 T2D patients and 20 age-matched healthy subjects. Plasma myostatin, lipid and glucose, and serum insulin were determined. T2D patients showed significantly higher fasting plasma glucose (FPG), serum insulin and triglyceride levels, and lower high-density lipoprotein levels than normal control subjects (P<0.01). Mean plasma myostatin level in T2D patients and health controls was (66.5±17.8) and (46.2±13.8) ng/mL, respectively. An unpaired t test showed that the increase of myostatin in the T2D patients was significant (P<0.001). In both healthy control and T2D groups, the female subjects showed higher myostatin levels than the male subjects. In the T2D patients, plasma level of myostatin was negatively correlated with body mass index (BMI, r=-0.42, P<0.01) and FPG (r=-0.51, P[Symbol: see text]0.01), but positively correlated with insulin resistance index (HOMA-IR, r=0.48, P<0.01). Up-regulation of plasma myostatin in the T2D patients and its correlation with BMI, FPG and blood insulin sensitivity suggests that plasma myostatin may be implicated in the pathogenesis of T2D and thus presented as a therapeutic target for treating the disease. Furthermore, circulating myostatin levels may be used as a biomarker for the disease.

Citing Articles

Therapeutic applications and challenges in myostatin inhibition for enhanced skeletal muscle mass and functions.

Wetzlich B, Nyakundi B, Yang J Mol Cell Biochem. 2024; 480(3):1535-1553.

PMID: 39340593 PMC: 11842502. DOI: 10.1007/s11010-024-05120-y.

Targeting Molecular Mechanisms of Obesity- and Type 2 Diabetes Mellitus-Induced Skeletal Muscle Atrophy with Nerve Growth Factor.

Jun L, Ding X, Robinson M, Jafari H, Knight E, Geetha T Int J Mol Sci. 2024; 25(8).

PMID: 38673892 PMC: 11050157. DOI: 10.3390/ijms25084307.

Diabetes Mellitus Should Be Considered While Analysing Sarcopenia-Related Biomarkers.

Rentflejsz J, Wojszel Z J Clin Med. 2024; 13(4).

PMID: 38398421 PMC: 10889814. DOI: 10.3390/jcm13041107.

[Adipomyokines in children with obesity].

Burmitskaya Y, Vasyukova O, Okorokov P, Zuraeva Z, Bezlepkina O Probl Endokrinol (Mosk). 2023; 69(4):87-95.

PMID: 37694871 PMC: 10520902. DOI: 10.14341/probl13250.

The bidirectional relationship between AMPK pathway activation and myokine secretion in skeletal muscle: How it affects energy metabolism.

Ahsan M, Garneau L, Aguer C Front Physiol. 2022; 13:1040809.

PMID: 36479347 PMC: 9721351. DOI: 10.3389/fphys.2022.1040809.

References

Lee S . Genetic analysis of the role of proteolysis in the activation of latent myostatin. PLoS One. 2008; 3(2):e1628. PMC: 2237902. DOI: 10.1371/journal.pone.0001628. View

Reardon K, Davis J, Kapsa R, Choong P, Byrne E . Myostatin, insulin-like growth factor-1, and leukemia inhibitory factor mRNAs are upregulated in chronic human disuse muscle atrophy. Muscle Nerve. 2001; 24(7):893-9. DOI: 10.1002/mus.1086. View

Welle S, Burgess K, Mehta S . Stimulation of skeletal muscle myofibrillar protein synthesis, p70 S6 kinase phosphorylation, and ribosomal protein S6 phosphorylation by inhibition of myostatin in mature mice. Am J Physiol Endocrinol Metab. 2009; 296(3):E567-72. PMC: 2660146. DOI: 10.1152/ajpendo.90862.2008. View

McPherron A, Lee S . Suppression of body fat accumulation in myostatin-deficient mice. J Clin Invest. 2002; 109(5):595-601. PMC: 150888. DOI: 10.1172/JCI13562. View

Hill J, Qiu Y, Hewick R, Wolfman N . Regulation of myostatin in vivo by growth and differentiation factor-associated serum protein-1: a novel protein with protease inhibitor and follistatin domains. Mol Endocrinol. 2003; 17(6):1144-54. DOI: 10.1210/me.2002-0366. View

Wagner K, Fleckenstein J, Amato A, Barohn R, Bushby K, Escolar D . A phase I/IItrial of MYO-029 in adult subjects with muscular dystrophy. Ann Neurol. 2008; 63(5):561-71. DOI: 10.1002/ana.21338. View

Boutayeb A, Boutayeb S . The burden of non communicable diseases in developing countries. Int J Equity Health. 2005; 4(1):2. PMC: 546417. DOI: 10.1186/1475-9276-4-2. View

Hayot M, Rodriguez J, Vernus B, Carnac G, Jean E, Allen D . Myostatin up-regulation is associated with the skeletal muscle response to hypoxic stimuli. Mol Cell Endocrinol. 2010; 332(1-2):38-47. DOI: 10.1016/j.mce.2010.09.008. View

Kim H, Liang L, Dean R, Hausman D, Hartzell D, Baile C . Inhibition of preadipocyte differentiation by myostatin treatment in 3T3-L1 cultures. Biochem Biophys Res Commun. 2001; 281(4):902-6. DOI: 10.1006/bbrc.2001.4435. View

10.

Williams M . Myostatin mutation associated with gross muscle hypertrophy in a child. N Engl J Med. 2004; 351(10):1030-1. View

11.

Morley J, Thomas D, Wilson M . Cachexia: pathophysiology and clinical relevance. Am J Clin Nutr. 2006; 83(4):735-43. DOI: 10.1093/ajcn/83.4.735. View

12.

McPherron A, Lawler A, Lee S . Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. Nature. 1997; 387(6628):83-90. DOI: 10.1038/387083a0. View

13.

Stumvoll M, Goldstein B, van Haeften T . Type 2 diabetes: principles of pathogenesis and therapy. Lancet. 2005; 365(9467):1333-46. DOI: 10.1016/S0140-6736(05)61032-X. View

14.

Huang Z, Chen D, Zhang K, Yu B, Chen X, Meng J . Regulation of myostatin signaling by c-Jun N-terminal kinase in C2C12 cells. Cell Signal. 2007; 19(11):2286-95. DOI: 10.1016/j.cellsig.2007.07.002. View

15.

Gonzalez-Cadavid N, TAYLOR W, Yarasheski K, Sinha-Hikim I, Ma K, Ezzat S . Organization of the human myostatin gene and expression in healthy men and HIV-infected men with muscle wasting. Proc Natl Acad Sci U S A. 1998; 95(25):14938-43. PMC: 24554. DOI: 10.1073/pnas.95.25.14938. View

16.

Allen D, Cleary A, Speaker K, Lindsay S, Uyenishi J, Reed J . Myostatin, activin receptor IIb, and follistatin-like-3 gene expression are altered in adipose tissue and skeletal muscle of obese mice. Am J Physiol Endocrinol Metab. 2008; 294(5):E918-27. DOI: 10.1152/ajpendo.00798.2007. View

17.

Philip B, Lu Z, Gao Y . Regulation of GDF-8 signaling by the p38 MAPK. Cell Signal. 2004; 17(3):365-75. DOI: 10.1016/j.cellsig.2004.08.003. View

18.

Lee S, McPherron A . Regulation of myostatin activity and muscle growth. Proc Natl Acad Sci U S A. 2001; 98(16):9306-11. PMC: 55416. DOI: 10.1073/pnas.151270098. View

19.

Milan G, Dalla Nora E, Pilon C, Pagano C, Granzotto M, Manco M . Changes in muscle myostatin expression in obese subjects after weight loss. J Clin Endocrinol Metab. 2004; 89(6):2724-7. DOI: 10.1210/jc.2003-032047. View

20.

Liu C, Yang Z, Liu C, Wang R, Tien P, Dale R . Effect of RNA oligonucleotide targeting Foxo-1 on muscle growth in normal and cancer cachexia mice. Cancer Gene Ther. 2007; 14(12):945-52. DOI: 10.1038/sj.cgt.7701091. View